Moffitt Presentation at AACR 2025

The Ecology of Cancer
Educational Session
Joel Brown
8:30-8:50 a.m.
Room S402 - McCormick Place South (Level 4)

LB051 / 10 - Quinolinic acid phosphoribosyl transferase (QPRT) expression is an essential liability of non-small cell lung cancer independently of its enzymatic function
Late Breaking Poster Session
Hossein Kashfi

647 / 13 - Intratumoral activation of anti-tumor CD4Th1 cells prior to neoadjuvant chemotherapy eradicate metastasis initiating cancer cells in breast cancer patients
Ganesan Ramamoorthi

235 / 3 - Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces immunogenic cell death
Jyoti Srivastava

1009 / 11 - DNA methylation-predicted plasma proteins and risk of colorectal cancer recurrence: Findings from the ColoCare Study 
Jacob K. Kresovich

991 / 25 - PARADIGM: an embeddings-based multimodal learning framework with foundation models and graph neural networks 
Asim Waqas

1183 - Non-canonical RNA binding of the MYBL2 transcription factor promotes melanoma 
4:10-4:25 p.m.
Room E352
McCormick Lakeside Center
(Level 3)
Kaizhen Wang

1143 - Reliable skeletal muscle area quantification and clinical data integration for predicting cancer cachexia
4:40-4:55 p.m.
Room S103
McCormick Place South
(Level 1)
Sabeen Ahmed

2486 / 7 - Decoding tumor evolution through fitness landscapes of aneuploid cells
Richard J. Beck 

1872 / 2 - MSH6 modulates PARP inhibitor sensitivity in BRCA-proficient high-grade serous ovarian cancer
Ou Deng

2107 / 10 - Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma
Ahmad A. Tarhini

2193 / 17 - Patient-derived colorectal microtumors predict response to anti-PD1 therapy
Duy T. Nguyen

3639 / 1 - A generative AI architecture integrates molecular, clinical and functional data to develop explainable predictive models and therapeutic strategies for multiple myeloma
Praneeth Reddy Sudalagunta

3641 / 3 - Predicting treatment outcomes using cross-modality correlations in multimodal oncology data  
Aakash Gireesh Tripathi

3714 / 13 - Microscopic mayhem: Serial killing and other immune cell dynamics captured in situ
W. Gregory Sawyer

3693 / 22 - Modeling VEGF dynamics in cancer: An evolutionary game theoretic approach
Ranjini Bhattacharya

3696 / 25 - Evolutionary immunotherapy in NSCLC: identifying optimal dosing strategies in TIL therapy using agent-based modeling
Sandhya Prabhakaran

3358 / 28 - Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma
Ahmad A. Tarhini

3365 / 2 - Preview of early adverse event landscape and association with clinical outcomes in advanced non-small cell lung cancer
Dung-Tsa Chen

3428 / 23 - Mechanistic insights into IFx-Hu2.0 responses in the first human trial after prior anti-PD-1 therapy failure  
Joseph Markowitz

3600 / 25 - Methylation-based biological age and risk of colorectal cancer recurrence: Findings from the ColoCare Study
Jacob K. Kresovich

2672 / 10 - Eco-evolutionary profiling of the UV-driven clonal dynamics and tumor initiation  
Stanislav S. Avdieiev

2674 / 12 - Cellular plasticity facilitates therapy resistance through enhancing adaptability
Alicia Bjornberg

2578 / 13 - GDF15 reprograms the microenvironment to drive the development of uveal melanoma liver metastases
Sathya Neelature Sriramareddy

Session Title: Novel Antitumor Agents
Minisymposium
2:30 - 4:45 p.m.
Room S103
McCormick Place South
(Level 1)
Derek Duckett

Session Title: Antigens, Antibodies, BiTEs, and Vaccines
Minisymposium
2:30 - 4:45 p.m.
Room S102
McCormick Place South
(Level 1)
Brian Czerniecki

3804 - Accumulation of branched chain keto acids promotes immunosuppression and neurodegeneration in leptomeningeal disease
Minisymposium
4:10 - 4:25 p.m.
Room  E450 B
McCormick Lakeside Center
(Level 4)
Mariam Lotfy Khaled

Session Title: Using Communication Effectively to Foster Trust in Science, Cultivate Engagement, and Improve Clinical Trial Participation
Special Session
5:00 - 6:30 p.m.
Room E350
McCormick Lakeside Center
(Level 3)
Bill Dalton (Chairperson/Opening Remarks)

Session Title: Is Cancer Evolution Driven by Evolutionary Genomic, Epigenomic Alterations or the Microenvironment? — A Cancer Evolution Working Group Town Hall and Networking Meeting
Town Meeting
7:30 – 7:40 p.m.
Room S104
McCormick Place South
(Level 1)
Andriy Marusyk (Invited Speaker)

4911 / 22 - Cancer disparities based on seven years of sexual orientation and gender identity collection at an NCI-Designated Comprehensive Cancer Center
Shahrzad A. Zamani

4269 / 26 - Defining the impact of autophagy blockade on triple negative breast cancer and remodeling of the tumor-immune microenvironment in primary and lung metastatic settings
Marilena Tauro 

4042 / 8 - Mitochondrial electron transport chain inhibition suppresses NRF2 expression in NSCLC
Chang Jiang

4937 / 15 - Circulating leukocyte composition and risk of colorectal cancer recurrence: Findings from the ColoCare Study
Jacob K. Kresovich

4904 / 15 - Say it ain’t psoas: addressing edema in pancreatic cancer body composition analyses
Evan W. Davis

4001 / 17 - Patient avatar models for ovarian cancer: Predicting patient response to treatment  
Erin M. George

Session Title:  Adaptive Therapy from Board to Bench to Bedside and Back Again
Major Symposium
12:30 - 2:00 p.m.
Room S103
McCormick Place South
(Level 1)
Alexander Anderson (Chairperson/Introduction/Presenter)

6402 - Stress-induced HDAC8 reprogramming drives IL-11-mediated immune escape in melanoma
Minisymposium
2:40 – 2:55 p.m.
Room S100A
(Grand Ballroom A)
McCormick Place South
(Level 1)
Michael F. Emmon

6238 / 2 - Interactions between ploidy and resource availability shape clonal interference in glioblastoma
Noemi Andor

6241 / 5 - Predicting treatment outcomes from adaptive therapy: a new mathematical biomarker
Kit Gallagher

6242 / 6 - Adaptive therapy in advanced basal cell carcinoma driven by imaging and mathematical modeling
Jill Gallaher

5836 / 12 - Suppression of TNFα and IFNγ signaling are key molecular events in KRASG12C mutant cancer cells to confer therapeutic resistance to Sotorasib and promote immune evasion
Mohammed L. Ibrahim

5509 / 4 - Mechanisms regulating resistance to KRAS inhibitor driven by DNp63/YAP regulation of tissue stiffness and metabolic alterations in lung adenocarcinoma
Santanu Adhikary

5512 / 7 - Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven byKRASG12C amplification or NRASG13R mutation
Hitendra Singh Solanki

5522 / 17 - Cell state modulates the KRASG12C proximal proteome
Anurima Majumder

6150 / 2 - Intramammary gland activation of invariant natural killer T cells with anti-tumor CD4Th1 cells prevents the development of invasive mammary carcinoma
Camille C. Baumrucker

6137 / 12 - Inhibition of FXR signaling in tumor-associated myeloid cells protects against melanoma progression  
Shiun Chang

5429 / 7 - NRF2 activation sensitizes the Fe-S cluster synthesis pathway to iron restriction  
Maddison A. T. Olley

6211 / 6 - Personalized risk models based on lung cancer screening history: post hoc analysis of the National Lung Screening Trial (NLST)
Sofia Haddan

5174 / 22 - Exploring extinction therapy for advanced cutaneous squamous cell carcinoma using UV-induced mouse models
Karol M. Prieto-Sarmiento

5101 / 6 - Collagen I helps maintain cancer dormancy under metabolic stress
Duy T. Nguyen

6981 / 10 - Discovery and optimization of purine-based CDK11 inhibitors for the treatment of Ewing’s sarcoma
Nada Elkholy

7289 / 4 - High CD8+ T cell TIM-3 expression predicts for sensitivity to TIM-3 based triplet checkpoint inhibitor combinations
Manali S. Phadke

7391 / 19 - Longitudinal changes in the gut microbiome among newly diagnosed colorectal cancer patients
Maria F. Gomez